Turn Therapeutics (TTRX)

Executive Summary

Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapeutics designed to deliver targeted anti-inflammatory effects for inflammatory skin diseases without systemic immune exposure or injections. The company's lead product candidate, GX-03, has completed a Phase 2 clinical trial for COVID-19 (NCT04951349) as an ointment formulation. Turn Therapeutics differentiates itself through a novel drug delivery approach that achieves local immune modulation, potentially reducing side effects associated with systemic therapies. With a market capitalization of approximately $110 million, the company is positioned to advance its pipeline into additional dermatological indications, including atopic dermatitis and psoriasis. The successful completion of the Phase 2 COVID-19 trial provides proof-of-concept for its platform, which may be leveraged to address unmet needs in chronic inflammatory skin conditions. Turn Therapeutics, headquartered in Westlake Village, California, trades under the ticker TTRX.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2/3 trial for GX-03 in atopic dermatitis45% success
• Q2 2027Partnership or licensing deal for GX-03 in dermatology50% success
• Q3 2026Preclinical data readout for next-generation topical cytokine modulator60% success